Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 2
2009 1
2012 1
2013 1
2014 6
2015 20
2016 50
2017 70
2018 97
2019 110
2020 170
2021 207
2022 188
2023 166
2024 156

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Results by year

Filters applied: . Clear all
Page 1
From Cardiorenal Syndrome to Chronic Cardiovascular and Kidney Disorder: A Conceptual Transition.
Zoccali C, Mallamaci F, Halimi JM, Rossignol P, Sarafidis P, De Caterina R, Giugliano R, Zannad F. Zoccali C, et al. Clin J Am Soc Nephrol. 2024 Jun 1;19(6):813-820. doi: 10.2215/CJN.0000000000000361. Epub 2023 Oct 30. Clin J Am Soc Nephrol. 2024. PMID: 37902772 Review.
We apply Occam's razor to the chronology-based construct to arrive at a simple definition on the basis of the coexistence of cardiovascular disease and CKD, the chronic cardiovascular-kidney disorder (CCKD). This conceptual framework builds upon the fact that car …
We apply Occam's razor to the chronology-based construct to arrive at a simple definition on the basis of the coexistence of cardiovascul …
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL, Butler J, Cherney DZI, Claggett BL, Fletcher RA, Herrington WG, Inzucchi SE, Jardine MJ, Mahaffey KW, McGuire DK, McMurray JJV, Neal B, Packer M, Perkovic V, Solomon SD, Staplin N, Vaduganathan M, Wanner C, Wheeler DC, Zannad F, Zhao Y, Heerspink HJL, Sabatine MS, Wiviott SD. Patel SM, et al. Circulation. 2024 Jun 4;149(23):1789-1801. doi: 10.1161/CIRCULATIONAHA.124.069568. Epub 2024 Apr 7. Circulation. 2024. PMID: 38583093 Free PMC article.
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear. METHODS: This was a collaborat …
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effe …
When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases.
Kobayashi M, Girerd N, Zannad F. Kobayashi M, et al. Nephrol Dial Transplant. 2024 Jun 28;39(7):1063-1072. doi: 10.1093/ndt/gfae004. Nephrol Dial Transplant. 2024. PMID: 38192033 Review.
Kidney disease frequently coexists with cardiovascular (CV) diseases, and this dual presence significantly amplifies the risk of adverse clinical outcomes. ...In this review, we aim to synthesize the existing body of evidence and chart the future trajectory for the …
Kidney disease frequently coexists with cardiovascular (CV) diseases, and this dual presence significantly amplifies the risk of adve …
Hemodynamic Support in Sepsis.
Antonucci E, Garcia B, Legrand M. Antonucci E, et al. Anesthesiology. 2024 Jun 1;140(6):1205-1220. doi: 10.1097/ALN.0000000000004958. Anesthesiology. 2024. PMID: 38743000 Review. No abstract available.
Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials.
Legrand M, Bagshaw SM, Bhatraju PK, Bihorac A, Caniglia E, Khanna AK, Kellum JA, Koyner J, Harhay MO, Zampieri FG, Zarbock A, Chung K, Liu K, Mehta R, Pickkers P, Ryan A, Bernholz J, Dember L, Gallagher M, Rossignol P, Ostermann M. Legrand M, et al. Crit Care. 2024 Mar 21;28(1):92. doi: 10.1186/s13054-024-04877-4. Crit Care. 2024. PMID: 38515121 Free PMC article. Review.
Acute kidney injury (AKI) often complicates sepsis and is associated with high morbidity and mortality. In recent years, several important clinical trials have improved our understanding of sepsis-associated AKI (SA-AKI) and impacted clinical care. ...We disc …
Acute kidney injury (AKI) often complicates sepsis and is associated with high morbidity and mortality. In recent years, several important …
Malignant Hypertension:A Systemic Cardiovascular Disease: JACC Review Topic of the Week.
Boulestreau R, Śpiewak M, Januszewicz A, Kreutz R, Guzik TJ, Januszewicz M, Muiesan ML, Persu A, Sarafidis P, Volpe M, Zaleska-Żmijewska A, van den Born BH, Messerli FH. Boulestreau R, et al. J Am Coll Cardiol. 2024 Apr 30;83(17):1688-1701. doi: 10.1016/j.jacc.2024.02.037. J Am Coll Cardiol. 2024. PMID: 38658108 Review.
Nonadherence to the antihypertensive regimen remains the most common cause for MHT, although antiangiogenic and immunosuppressant therapy can also trigger hypertensive emergencies. Depending on the clinical presentation, parenteral or oral therapy can be used to initiate B …
Nonadherence to the antihypertensive regimen remains the most common cause for MHT, although antiangiogenic and immunosuppressant therapy ca …
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.
Apperloo EM, Neuen BL, Fletcher RA, Jongs N, Anker SD, Bhatt DL, Butler J, Cherney DZI, Herrington WG, Inzucchi SE, Jardine MJ, Liu CC, Mahaffey KW, McGuire DK, McMurray JJV, Neal B, Packer M, Perkovic V, Sabatine MS, Solomon SD, Staplin N, Szarek M, Vaduganathan M, Wanner C, Wheeler DC, Wiviott SD, Zannad F, Heerspink HJL. Apperloo EM, et al. Lancet Diabetes Endocrinol. 2024 Aug;12(8):545-557. doi: 10.1016/S2213-8587(24)00155-4. Epub 2024 Jul 8. Lancet Diabetes Endocrinol. 2024. PMID: 38991584
The two main cardiovascular outcomes assessed included major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death), and hospitalisation for heart failure or cardiovascular death. ...These findings sugg …
The two main cardiovascular outcomes assessed included major adverse cardiovascular events (nonfatal myocardial infarction, no …
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.
Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Solomon SD, McMurray JJV. Jhund PS, et al. Lancet. 2024 Sep 21;404(10458):1119-1131. doi: 10.1016/S0140-6736(24)01733-1. Epub 2024 Sep 1. Lancet. 2024. PMID: 39232490 Free article.
The primary outcome of this meta-analysis was a composite of time to first hospitalisation for heart failure or cardiovascular death. We also estimated the effect of MRAs on components of this composite, total (first or repeat) heart failure hospitalisations (with and with …
The primary outcome of this meta-analysis was a composite of time to first hospitalisation for heart failure or cardiovascular death. …
Management of hypertensive disorders in pregnancy: a Position Statement of the European Society of Hypertension Working Group 'Hypertension in Women'.
Thomopoulos C, Hitij JB, De Backer T, Gkaliagkousi E, Kreutz R, Lopez-Sublet M, Marketou M, Mihailidou AS, Olszanecka A, Pechère-Bertschi A, Pérez MP, Persu A, Piani F, Socrates T, Stolarz-Skrzypek K, Cífková R. Thomopoulos C, et al. J Hypertens. 2024 Jul 1;42(7):1109-1132. doi: 10.1097/HJH.0000000000003739. Epub 2024 Apr 11. J Hypertens. 2024. PMID: 38690949 Review.
The pathophysiological substrate and the clinical presentation of HDP are multifarious. The latter and the lack of well designed clinical trials in the field explain the absence of consensus on disease management among relevant international societies. Thus, the usu …
The pathophysiological substrate and the clinical presentation of HDP are multifarious. The latter and the lack of well designed c …
The current best drug treatment for hypertensive heart failure with preserved ejection fraction.
Rist A, Sevre K, Wachtell K, Devereux RB, Aurigemma GP, Smiseth OA, Kjeldsen SE, Julius S, Pitt B, Burnier M, Kreutz R, Oparil S, Mancia G, Zannad F. Rist A, et al. Eur J Intern Med. 2024 Feb;120:3-10. doi: 10.1016/j.ejim.2023.10.008. Epub 2023 Oct 19. Eur J Intern Med. 2024. PMID: 37865559 Free article. Review.
The most frequent concomitant conditions are type-2 diabetes mellitus, obesity, atrial fibrillation, and coronary disease. HF outcome research focuses on decreasing mortality and preventing hospitalization for worsening HF syndrome. ...For various reasons, these drug treat …
The most frequent concomitant conditions are type-2 diabetes mellitus, obesity, atrial fibrillation, and coronary disease. HF outcome res …
156 results